Immunethep is available to establish collaborations with other pharmaceutical companies to accelerate the development of specific products targeting both the human and animal markets.
We established collaborations with Merck & Co. (MSD), Merck Animal Health, GSK and Vetoquinol
Please contact us at email@example.com
IMMUNETHEP is developing innovative immunotherapies to approach infectious diseases. To accomplish this, the company has a team of highly-qualified scientists working on cutting-edge technologies.
We are committed to a continued effort in Research and Development to discover new targets, modes of action, and potential therapies and better comprehend the science behind all those discoveries, allowing for the expansion of our IP portfolio.
Immunethep has established collaborations with Universities and Research Institutions over the years. We would like to mention in particular the strong ties with the University of Porto and the Institute for Research and Innovation in Health (i3S).
We are always looking for new ways to collaborate in order to develop immunotherapies for infectious diseases.
IMMUNETHEP is currently looking for partner institutions (Hospitals, Clinics, and Patients Associations) to conduct Clinical Trials for the products in its pipeline. Please contact us if your institution is interested in knowing more about this opportunity.
If you wish to volunteer for a clinical trial, please send us an email: firstname.lastname@example.org
Portugal’s Biotechnology Industry Organization (P-BIO) is a national association that brings together the vast majority of companies linked to the biotechnology and life sciences sector. Since it was founded in 1999, it has been the cornerstone for the development and support of biotechnology in Portugal.
P-BIO seeks to develop an environment that is favorable to the creation and growth of start-ups, promoting their corporate development domestically and internationally.
Launched in June 2015, the BEAM Alliance (Biotech companies from Europe innovating in Anti-Microbial resistance research) represents over 60 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (AMR), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based, and phage-based therapies, immune targeting therapies, anti-biofilm agents and medical devices including in vitro diagnostics.
Portugal 2020 was the national programme of EU funds destined to support the Portuguese economy under the framework for the period 2014-2020, in particular for R&D and innovation initiatives. Immunethep has received funds for 3 projects under this program:
The Bill and Melinda Gates Foundation (BMGF) has supported Immunethep through an R&D grant to assess if oral delivered anti-GAPDH antibodies can prevent GBS infections.
The European Innovation Council (EIC) has selected Immunethep to receive funding from its EIC Accelerator programme. Immunethep is receiving an initial Grant and is eligible for additional Equity investment from the EIC Fund for a project that comprises a total investment of €17.5 million.